ABUS Arbutus Biopharma Corp
Nasdaq · SEC CIK 1447028 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 62 since 2021-10-20, latest 2026-09-23 20:32
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Nguyen Tuan | CFO | — | — |
| Androski Lindsay | Pres, CEO, Dir | — | — |
| Sawhney Roger | Dir | — | — |
| Beardsley Robert A | Dir | — | — |
Transactions 36
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-09-23 20:32 | 2026-09-18 | ABUS | Androski Lindsay | Pres, CEO, Dir | M - OptEx | $3.30 | +126.9K | 154.9K | +453% | +$418.4K |
| D | 2026-09-23 20:32 | 2026-09-18 | ABUS | Androski Lindsay | Pres, CEO, Dir | F - Tax | $5.07 | -82.5K | 72.3K | -53% | -$418.4K |
| DM | 2026-09-23 20:31 | 2026-09-18 | ABUS | Nguyen Tuan | CFO | M - OptEx | $3.57 | +293.1K | 366.6K | +399% | +$1.05M |
| D | 2026-09-23 20:31 | 2026-09-18 | ABUS | Nguyen Tuan | CFO | F - Tax | $5.07 | -206.6K | 160.0K | -56% | -$1.05M |
| DM | 2026-09-23 20:31 | 2026-09-18 | ABUS | Sawhney Roger | Dir | M - OptEx | $3.88 | +131.3K | 131.3K | New | +$509.6K |
| D | 2026-09-23 20:31 | 2026-09-18 | ABUS | Sawhney Roger | Dir | F - Tax | $5.07 | -100.5K | 30.8K | -77% | -$509.6K |
| DM | 2026-09-23 20:31 | 2026-09-18 | ABUS | Beardsley Robert A | Dir | M - OptEx | $3.82 | +131.3K | 131.3K | New | +$502.2K |
| D | 2026-09-23 20:31 | 2026-09-18 | ABUS | Beardsley Robert A | Dir | F - Tax | $5.07 | -99.1K | 32.3K | -75% | -$502.2K |
| D | 2026-02-02 | 2026-02-02 | ABUS | Nguyen Tuan | CFO | A - Grant | $0.00 | +73.5K | 73.5K | New | $0 |
| D | 2026-02-02 | 2026-02-02 | ABUS | Androski Lindsay | Pres, CEO, Dir | A - Grant | $0.00 | +28.0K | 28.0K | New | $0 |
| D | 2025-02-19 | 2025-02-14 | ABUS | McElhaugh Michael J. | CEO, Interim Pres, Dir | A - Grant | $0.00 | +177.0K | 1.66M | +12% | $0 |
| D | 2025-02-19 | 2025-02-14 | ABUS | Naftzger J. Christopher | GC, CCO | A - Grant | $0.00 | +54.3K | 140.5K | +63% | $0 |
| D | 2025-02-19 | 2025-02-14 | ABUS | Sims Karen | Chief Medical Off | A - Grant | $0.00 | +49.3K | 155.5K | +46% | $0 |
| D | 2025-02-19 | 2025-02-14 | ABUS | HASTINGS DAVID C | CFO | A - Grant | $0.00 | +90.1K | 249.8K | +56% | $0 |
| 2025-02-05 | 2025-02-04 | ABUS | Naftzger J. Christopher | GC, CCO | S - Sale | $3.28 | -11.3K | 86.2K | -12% | -$37.2K | |
| 2025-02-05 | 2025-02-04 | ABUS | Sims Karen | Chief Medical Off | S - Sale | $3.28 | -19.3K | 106.2K | -15% | -$63.5K | |
| 2025-02-05 | 2025-02-04 | ABUS | McElhaugh Michael J. | CEO, Interim Pres, Dir | S - Sale | $3.28 | -23.8K | 1.48M | -2% | -$78.0K | |
| 2025-02-05 | 2025-02-04 | ABUS | HASTINGS DAVID C | CFO | S - Sale | $3.28 | -22.2K | 159.7K | -12% | -$72.8K | |
| D | 2024-08-16 | 2024-08-14 | ABUS | MANCHESTER KEITH S | Dir | S - Sale+OE | $3.69 | -8,846 | 46.1K | -16% | -$32.6K |
| D | 2024-08-16 | 2024-08-14 | ABUS | MANCHESTER KEITH S | Dir | M - OptEx | $0.56 | +54.9K | 54.9K | New | +$30.8K |
| D | 2024-02-05 | 2024-02-01 | ABUS | Sims Karen | Chief Medical Off | A - Grant | $0.00 | +101.0K | 129.9K | +349% | $0 |
| D | 2024-02-05 | 2024-02-02 | ABUS | Sims Karen | Chief Medical Off | S - Sale | $2.31 | -4,358 | 125.5K | -3% | -$10.1K |
| D | 2024-02-05 | 2024-02-01 | ABUS | McElhaugh Michael J. | CEO, Interim Pres, Dir | A - Grant | $0.00 | +123.8K | 1.51M | +9% | $0 |
| D | 2024-02-05 | 2024-02-02 | ABUS | McElhaugh Michael J. | CEO, Interim Pres, Dir | S - Sale | $2.31 | -10.2K | 1.50M | -0.7% | -$23.5K |
| D | 2024-02-05 | 2024-02-01 | ABUS | HASTINGS DAVID C | CFO | A - Grant | $0.00 | +112.5K | 191.5K | +142% | $0 |
| D | 2024-02-05 | 2024-02-02 | ABUS | HASTINGS DAVID C | CFO | S - Sale | $2.31 | -9,593 | 181.9K | -5% | -$22.2K |
| D | 2024-02-05 | 2024-02-01 | ABUS | Sofia Michael J. | CSO | A - Grant | $0.00 | +109.5K | 1.50M | +8% | $0 |
| D | 2024-02-05 | 2024-02-02 | ABUS | Sofia Michael J. | CSO | S - Sale | $2.31 | -9,982 | 1.49M | -0.7% | -$23.1K |
| D | 2024-02-05 | 2024-02-01 | ABUS | Naftzger J. Christopher | GC, CCO | A - Grant | $0.00 | +95.1K | 95.1K | New | $0 |
| D | 2023-02-03 | 2023-02-01 | ABUS | HASTINGS DAVID C | CFO | A - Grant | $0.00 | +79.0K | 79.0K | New | $0 |
| D | 2023-02-03 | 2023-02-01 | ABUS | Collier William H. | Pres, CEO, Dir | A - Grant | $0.00 | +216.5K | 216.5K | New | $0 |
| D | 2023-02-03 | 2023-02-01 | ABUS | McElhaugh Michael J. | Chief Business Off | A - Grant | $0.00 | +83.7K | 1.39M | +6% | $0 |
| D | 2023-02-03 | 2023-02-01 | ABUS | Howard Elizabeth | EVP, GC, Compliance | A - Grant | $0.00 | +69.7K | 86.0K | +427% | $0 |
| D | 2023-02-03 | 2023-02-01 | ABUS | Sofia Michael J. | CSO | A - Grant | $0.00 | +82.2K | 1.39M | +6% | $0 |
| 2021-12-03 | 2021-12-01 | ABUS | Sofia Michael J. | CSO | S - Sale | $5.09 | -200.0K | 1.30M | -13% | -$1.02M | |
| D | 2021-10-20 | 2021-10-18 | ABUS | Roivant Sciences Ltd. | 10% | C - Cnv Deriv | — | +22.83M | 38.85M | +143% | — |
Purchase Sale Sale after option exercise All abbreviations